// App-Quantinova.ai

: BET PROTEIN INHIBITION AND COGNITION: A PRE-SPECIFIED SUBSTUDY OF THE BETONMACE PHASE 3 TRIAL EVALUATING APABETALONE IN PATIENTS WITH DIABETES AND ACUTE CORONARY SYNDROME

Researchers

Presenter

  • Kausik K. Ray

Principal Investigators

  • Stephen Nicholls

  • Michael Sweeney

  • Jan Johansson

  • Norman Wong

  • Ewelina Kulikowski

  • Kenneth Lebioda

  • Peter Toth

  • Henry Ginsberg

  • Kamyar Kalantar-Zadeh

  • Mathias L. Haarhaus

  • Bengt Winblad

  • Jeffrey L. Cummings

  • Gregory Schwartz

Medical Centers

  • Resverlogix Corp., Calgary, Canada

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Acute Coronary Syndromes

  • Myocardial infarction

  • Diabetes

  • Stroke

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

Drug/Treatment

  • RVX-208

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved